Metformin activates AMP-activated protein kinase (AMPK), a master metabolic regulator that coordinates mitochondrial biogenesis, autophagy, and shifts cellular energy metabolism toward oxidative phosphorylation while suppressing mTOR signaling. This mechanism directly modulates nutrient sensing and metabolic aging pathways, reducing anabolic stress and extending replicative lifespan in cell culture and organism models. In humans, observational data and the ongoing TAME trial suggest metformin use associates with reduced age-related morbidity, lower cardiovascular and cancer incidence, and improved metabolic markers; however, prospective evidence for lifespan extension in non-diabetic populations remains incomplete. The drug's effect on human healthspan appears most robust in contexts of glucose dysregulation and metabolic syndrome, where it reverses pathological aging acceleration.
Yes. Metformin is FDA-approved for type 2 diabetes management. Its use specifically for healthspan or longevity purposes outside diabetes management is off-label.
The most-cited pooled estimate tracked on Geroevidence shows a hazard ratio of 0.93 (95% CI 0.88–0.99) from meta-analytic data (Campbell 2017). See the full profile for source context and study population.
The TAME (Targeting Aging with Metformin) trial has been proposed and discussed extensively in the geroscience literature as a dedicated test of metformin's longevity effects. Status and design details are tracked in the full profile.
Metformin's side-effect profile is well established from its approved diabetes indication. Gastrointestinal effects (nausea, diarrhea) are most common, and rare cases of lactic acidosis have been reported, primarily in patients with renal impairment.
GLP-1 agonists currently hold a Strong evidence tier with a hard cardiovascular outcome (MACE), while metformin is graded Moderate based on meta-analytic mortality data. See the GLP-1 agonists profile for direct comparison.